Search
Cell biologist Michael Overholtzer explains apoptosis, a form of programmed cell death that can lead to cancer when it doesn’t function properly.
Memorial Sloan Kettering investigators hope their new web tool will improve the accessibility of large-scale genome-sequencing information for cancer researchers everywhere, and accelerate research and therapeutic discovery.
The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.
A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.
Ten scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 15, 2024, as part of Memorial Sloan Kettering’s 45th annual academic convocation.
Scientists and scholars received degrees and awards at MSK's 40th annual ceremony, held on May 29.
The in-person event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.
Harold Varmus became President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center on January 1, 2000. He ended his decade-long tenure on July 1, 2010. And on July 12, 2010, Dr. Varmus took up a new role as Director of the National Cancer Institute.
Scientists have learned that a drug activates a form of highly inflammatory programmed cell death called pyroptosis — a discovery that sheds light on immune function.
New findings from researchers at the Sloan Kettering Institute provide insight into a fundamental biological process called the epithelial-mesenchymal transition.